clinical trial · NCT07024316
A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP
Atlas Molecular Pharma·phase2·recruiting·n = 6
Congenital Erythropoietic Porphyria (CEP)ATL-001 (Ciclopirox oral solution)
brief summary
This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD
started
Jan 29, 2026
primary completion
May 1, 2028
completion
Jun 1, 2028
last updated
Mar 24, 2026
official title
A Phase I-II, N-of-1, Open-Label, Prospective Study to Evaluate the Efficacy and Safety of ATL-001 in Adult Patients With Congenital Erythropoietic Porphyria (CEP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol